Johnson & johnson announces extension of abiomed tender offer to december 21, 2022

New brunswick, n.j.--( business wire )--johnson & johnson (nyse: jnj), the world's largest, most diversified healthcare products company, today announced that athos merger sub, inc. (“offeror”), a wholly owned subsidiary of johnson & johnson, has extended the expiration date of its offer (the “offer”) to acquire all of the outstanding shares of common stock of abiomed, inc. (nasdaq: abmd), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved.
ABMD Ratings Summary
ABMD Quant Ranking